Ranked #1 in 8 out of the 10 evaluated specialties by U.S. News
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
Learn more about our ranking as a top pediatric hospital here.
The Retinoblastoma Program at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center offers patients access to the latest therapies – including intra-arterial chemotherapy - and proven pediatric expertise in treating these malignant tumors of the retina. Thanks in part to our leading-edge research and clinical care, nine out of 10 children with retinoblastoma survive into adulthood.
Dana-Farber/Boston Children’s is an integrated pediatric hematology and oncology partnership between Dana-Farber Cancer Institute and Boston Children’s Hospital. We offer, in one specialized program, the full spectrum of services that are needed for diagnosis, treatment and ongoing care of even the rarest and hard-to-treat conditions.
Patients in the Retinoblastoma Program are treated by a team of pediatric oncologists who specialize in the treatment of retinoblastoma, as well as pediatric ophthalmologists, surgical oncologists, pediatric oncology nurses, radiation oncologists and other medical specialists. We also have genetic counselors who perform genetic testing to look for the retinoblastoma gene, confirm the diagnosis and determine if a genetic mutation is inherited.
In addition to laboratory and clinical research, our program participates in a retinoblastoma research consortium with other Boston hospitals. Our clinicians and researchers focus their work on improving therapeutic approaches and outcomes for patients, including studies on a class of drugs that prevents new blood vessel formation that feed retinoblastoma tumors and biologic therapies that direct the body’s immune system to fight the cancer.
Learn more about our Retinoblastoma Program on the Dana-Farber/Boston Children’s website.
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”